- Home
- HHS vs GDTC Comparison
HHS vs GDTC Comparison
Compare HHS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- GDTC
- Stock Information
- Founded
- HHS 1923
- GDTC 2018
- Country
- HHS United States
- GDTC Singapore
- Employees
- HHS N/A
- GDTC N/A
- Industry
- HHS Advertising
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- GDTC Health Care
- Exchange
- HHS Nasdaq
- GDTC Nasdaq
- Market Cap
- HHS 28.4M
- GDTC 21.5M
- IPO Year
- HHS N/A
- GDTC 2023
- Fundamental
- Price
- HHS $3.29
- GDTC $1.89
- Analyst Decision
- HHS
- GDTC Buy
- Analyst Count
- HHS 0
- GDTC 1
- Target Price
- HHS N/A
- GDTC $5.00
- AVG Volume (30 Days)
- HHS 8.0K
- GDTC 18.1K
- Earning Date
- HHS 08-07-2025
- GDTC 01-01-0001
- Dividend Yield
- HHS N/A
- GDTC N/A
- EPS Growth
- HHS N/A
- GDTC N/A
- EPS
- HHS N/A
- GDTC N/A
- Revenue
- HHS $181,355,000.00
- GDTC $368,838.00
- Revenue This Year
- HHS $6.54
- GDTC $5.37
- Revenue Next Year
- HHS N/A
- GDTC N/A
- P/E Ratio
- HHS N/A
- GDTC N/A
- Revenue Growth
- HHS N/A
- GDTC N/A
- 52 Week Low
- HHS $3.06
- GDTC $1.20
- 52 Week High
- HHS $8.49
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- HHS 36.41
- GDTC 37.08
- Support Level
- HHS $3.20
- GDTC $1.85
- Resistance Level
- HHS $3.55
- GDTC $1.95
- Average True Range (ATR)
- HHS 0.24
- GDTC 0.10
- MACD
- HHS 0.01
- GDTC -0.02
- Stochastic Oscillator
- HHS 23.71
- GDTC 28.00
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.